Fox Chase Cancer Center

University of California

Elucida Oncology, Inc.

Institute for Cancer Research

Gregory P Adams

James David Marks

Louis M Weiner

Eva M Horak

Heidi H Simmons

Aranapakam Mudumbai Venkatesan

Wayne A Marasco

Francis Y F Lee

Roland L Dunbrack

Matthew K Robinson

Qing-an Yuan

Kai Ma

Feng Chen

Fei Wu

Melik Ziya Türker

Thomas Courtney Gardinier, Ii

Geno J Germano, Jr

Smita Mehta

Andreas Lehmann

Jared Adolf-Bryfogle

The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.

Folate receptor targeted nanoparticle drug conjugates and uses thereof

Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a M&#xfc;llerian-inhibiting substance type II receptor binding region of the M&#xfc;llerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.

Chimera of bone morphogenic protein 2 and the M&#xfc;llerian-inhibiting substance type II receptor binding region of M&#xfc;llerian-inhibiting substance

Methods for generating hybrid antibodies are provided.

Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies

Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.

Bispecific single chain Fv antibody molecules and methods of use therof

Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.

Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof

Bispecific single chain Fv antibody molecules and methods of use thereof

Compositions and methods for detecting and treating cancers expressing Mullerian inhibiting substance Type II receptor (MISIIR) are provided.

Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer

Growing community of inventors

Hatboro, PA, United States of America

Gregory P Adams